13F Holdings
中文EN

LFCR LIFECORE BIOMEDICAL, INC. \DE\

Pharmaceutical Preparations · Nasdaq · SEC CIK 1005286 · Fiscal year ends 05/25

Financial factors as of 2025-05-25 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.5%
TTM net income YoY-422.3%
TTM EPS YoY-484.8%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—

Margins

Gross margin31.3%
Operating margin-13.4%
Net margin-30.0%
FCF margin-10.6%
EBITDA margin-7.2%

Returns

ROE-612.1%
ROA-15.7%
ROIC (approx.)-10.7%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets80.2%
Debt / equity100.20x
Current ratio2.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.00x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue10.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-05-25FY20242024-05-26FY20232023-05-28FY20222022-05-29FY20212021-05-30
Income statement
Revenue$128.87M$128.26M$103.27M$111.27M$100.87M
Cost of revenue$88.57M$86.41M$75.28M$72.20M$61.94M
Gross profit$40.30M$41.85M$27.98M$39.07M$38.94M
R&D expense$8.26M$8.57M$8.74M$7.84M$6.68M
SG&A expense$44.05M$40.46M$38.97M$34.66M$27.72M
Operating income-$17.25M-$8.84M-$21.80M-$11.79M-$8.82M
Interest expense$22.17M$18.15M$17.65M$15.55M$8.93M
Pretax income-$38.67M$9.51M-$63.93M-$20.69M-$29.79M
Income tax$43,000$183,000$308,000-$5.21M-$6.35M
Net income-$38.72M$12.01M-$99.56M-$116.72M-$32.29M
EBITDA-$9.22M-$890,000-$8.62M$6.27M$11.04M
EPS (basic)-1.270.39-3.32-3.97-1.10
EPS (diluted)-1.270.33-3.32-3.97-1.10
Weighted avg. shares (diluted)34.82M36.66M29.96M29.47M29.29M
Balance sheet
Cash & equivalents$8.27M$8.46M$19.09M$1.64M$1.29M
Receivables—$31.15M$29.02M$38.31M$31.59M
Inventory$32.29M$39.98M$40.84M$36.00M$33.93M
Current assets$85.68M$81.03M$93.88M$116.67M$145.30M
PP&E, net$129.01M$149.16M$134.39M$118.67M$107.13M
Goodwill$13.88M$13.88M$13.88M$13.88M$13.88M
Intangibles$4.20M$4.20M$4.20M$1.07M$8.04M
Total assets$239.34M$253.96M$253.54M$274.70M$501.88M
Current liabilities$30.18M$38.87M$39.29M$176.58M$101.85M
Short-term debt$3.44M$943,000$580,000$98.18M$0
Long-term debt$130.44M$124.67M$84.26M$0$164.90M
Total debt$133.87M$125.61M$84.84M$98.18M$164.90M
Total liabilities$191.91M$200.06M$218.46M$186.88M$299.94M
Shareholders' equity$1.34M$11.31M-$4.23M$87.82M$201.95M
Net debt$125.61M$117.15M$65.75M$96.53M$163.61M
Shares outstanding37.03M30.56M30.32M29.51M29.33M
Cash flow statement
Operating cash flow-$206,000$257,000-$17.44M-$22.59M$16.47M
Capital expenditure$13.41M$18.39M—$26.23M$19.26M
Free cash flow-$13.62M-$18.14M—-$48.82M-$2.79M
Investing cash flow-$6.42M-$18.39M-$4.81M$79.96M-$12.31M
Financing cash flow$6.42M$7.51M$39.70M-$57.02M-$3.42M
Depreciation & amortization$8.03M$7.95M$13.18M$18.06M$19.87M
Stock-based compensation$10.16M$6.20M$3.61M$2.61M$3.36M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.